FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies [Yahoo! Finance]
FibroBiologics, Inc. (FBLG)
Company Research
Source: Yahoo! Finance
pre-IND enabling development, marking a critical step toward clinical translation of the Bone Marrow Organoid technology HOUSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced significant advancements in its Bone Marrow Organoid platform, which may offer promising new treatment options for hematopoietic cancers and age-related immune decline. The company's proprietary Bone Marrow Organoids have demonstrated potential in multiple therapeutic applications: Our Pre-IND animal trials show that Transplantation of Bone Marrow Organoids into xenografted melanoma mouse model significantly reduced tumor size. The organoids enable efficient ex vivo gene editing, allowing for swift and targeted therapeutic interven
Show less
Read more
Impact Snapshot
Event Time:
FBLG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBLG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBLG alerts
High impacting FibroBiologics, Inc. news events
Weekly update
A roundup of the hottest topics
FBLG
News
- FibroBiologics Announces Payoff of Outstanding DebtGlobeNewswire
- FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.MarketBeat
FBLG
Earnings
- 5/14/25 - Miss
FBLG
Sec Filings
- 12/3/25 - Form D
- 12/3/25 - Form D
- 11/25/25 - Form 8-K
- FBLG's page on the SEC website